• Thursday, March 2, 2023 @ 12:00 am


Cosmo reported record preliminary 2022 results with key drivers such as Winlevi off to a solid start in the US. Legacy products such as Lialda, and Uceris/Cortiment added to the record revenues. Cosmo is one of the few profitable SIX-listed biopharma companies with sufficient cash to fund its development plans and pay dividends.

Key catalysts include:

1. Start phase III trial Breezula in male alopecia (Q1 2023)
2. Winlevi licensing agreements (2023)
3. Winlevi filing for EU approval (H2 2023)

To the full Cosmo Valuation Report